Komori
Fuso Pharmaceutical Industries (4538) · FactRestated

No material impact of COVID-19 on the financial statements

First written in FY2020. 9 of 10 entries say "Restated". Latest entry: FY2023-Q3.

10entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY2023-Q32020: 320202021: 320212022: 320222023: 12023
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1254 companies write about · 1266 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1280 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3RestatedAnnual report

    「During the cumulative third quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the third quarter, the infection had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread on demand, procurement, production and supply.
  2. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the second quarter, the infection had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread on demand, procurement, production and supply.
  3. FY2023-Q1RestatedAnnual report

    「During the cumulative first quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the first quarter, the infection had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread on demand, procurement, production and supply.
  4. FY2022RestatedAnnual report

    「Although the global spread of COVID-19 has made the situation unpredictable, it has not had a material impact on the financial statements for the current fiscal year.」

    The company recognizes the spread of COVID-19 but states that it has not had a material impact on the FY2022 financial statements.
  5. FY2022-Q2RestatedAnnual report

    「During the cumulative second quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the second quarter, the infection had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread on demand, procurement, production and supply.
  6. FY2021RestatedAnnual report

    「Although the global spread of COVID-19 has made the situation unpredictable, it has not had a material impact on the financial statements for the current fiscal year.」

    The company recognizes the spread of COVID-19 but states that it has not had a material impact on the FY2021 financial statements.
  7. FY2021-Q3RestatedAnnual report

    「During the cumulative third quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the third quarter, COVID-19 had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread of the infection on demand, procurement, production and supply.
  8. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the second quarter, COVID-19 had no material impact on operating results, while continuing to describe the potential impact of a prolonged or more serious spread of the infection on demand, procurement, production and supply.
  9. FY2021-Q1RestatedAnnual report

    「During the cumulative first quarter, COVID-19 had no material impact on the company’s operating results. However, if the spread of the infection continues for longer or becomes more serious, the company’s business could be materially affected by reduced or restricted activities, patients refraining from seeking medical care and other factors, as well as by delays in procuring raw materials and the suspension of product supplies due to infections occurring at production facilities.」

    The company states that, as of the first quarter, COVID-19 had no material impact on operating results, while describing the potential impact of a prolonged or more serious spread of the infection on demand, procurement, production and supply.
  10. FY2020First statedAnnual report

    「Although the global spread of COVID-19 has made the situation unpredictable, it has not had a material impact on the financial statements for the current fiscal year.」

    The company recognizes the global spread of COVID-19 but states that it has not had a material impact on the financial statements for the current fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
No material impact of COVID-19 on the financial statements | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori